Lyell Wealth Management LP Purchases 1,962 Shares of Zoetis Inc. (NYSE:ZTS)

Lyell Wealth Management LP increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 55,791 shares of the company’s stock after buying an additional 1,962 shares during the period. Zoetis comprises 1.3% of Lyell Wealth Management LP’s portfolio, making the stock its 24th biggest holding. Lyell Wealth Management LP’s holdings in Zoetis were worth $11,011,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of ZTS. Vaughan Nelson Investment Management L.P. acquired a new position in Zoetis during the third quarter valued at approximately $176,219,000. Alphinity Investment Management Pty Ltd boosted its position in Zoetis by 214.7% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 824,148 shares of the company’s stock valued at $162,662,000 after purchasing an additional 562,259 shares during the last quarter. International Assets Investment Management LLC boosted its position in Zoetis by 27,671.0% during the fourth quarter. International Assets Investment Management LLC now owns 479,328 shares of the company’s stock valued at $94,605,000 after purchasing an additional 477,602 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Zoetis by 34.8% in the third quarter. Envestnet Asset Management Inc. now owns 1,562,044 shares of the company’s stock valued at $271,764,000 after buying an additional 403,164 shares during the last quarter. Finally, Natixis Advisors L.P. lifted its position in shares of Zoetis by 53.9% in the third quarter. Natixis Advisors L.P. now owns 941,219 shares of the company’s stock valued at $163,753,000 after buying an additional 329,543 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the transaction, the executive vice president now owns 15,723 shares in the company, valued at approximately $2,725,267.59. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 2,209 shares of company stock worth $371,293 in the last 90 days. Company insiders own 0.15% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS traded up $1.33 during mid-day trading on Wednesday, hitting $150.89. 3,640,337 shares of the stock were exchanged, compared to its average volume of 3,074,906. The stock has a market capitalization of $69.01 billion, a price-to-earnings ratio of 29.76, a price-to-earnings-growth ratio of 2.22 and a beta of 0.85. The firm’s 50-day simple moving average is $173.11 and its 200 day simple moving average is $179.58. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same quarter last year, the business earned $1.15 EPS. Zoetis’s revenue was up 8.5% on a year-over-year basis. As a group, equities analysts anticipate that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.15%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Stifel Nicolaus cut their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Barclays cut their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday. The Goldman Sachs Group raised their price objective on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, Piper Sandler reissued an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $218.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.